resistance
No description yet: the sentence for this tag has not been written. 6 records carry it: 3 biomarkers, 2 people, 1 target.
By kind
6 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Alan D. D'Andrea Director, Susan F. Smith Center for Women's Cancers and Center for DNA Damage and Repair, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Mapped the Fanconi anaemia/BRCA DNA repair pathway and how tumours become resistant to PARP inhibitors. | Ovarian cancer | none | dna-repair, parp | ||
Alberto Bardelli Scientific Director, IFOM ETS - The AIRC Institute of Molecular Oncology; Professor, University of Turin · Istituto di Candiolo IRCCS (FPO) Used ctDNA to show how colorectal cancers evolve resistance to EGFR antibodies and how that resistance can fade. | Colorectal cancer | none | ctdna, colorectal | ||
BCR::ABL1 T315I BCR-ABL1 T315I is the gatekeeper mutation in the ABL1 kinase that defeats imatinib, dasatinib, nilotinib and bosutinib. Ponatinib and asciminib are the two drugs approved for it. | Chronic myeloid leukaemia, Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia, accelerated and blast phase | none | biomarker, cml | ||
EGFR T790M EGFR T790M is the gatekeeper mutation that lung cancers acquire to escape first- and second-generation EGFR inhibitors. Finding it, in tissue or blood, is the historic gate for osimertinib after an earlier EGFR drug. | Non-small-cell lung cancer | none | biomarker, egfr | ||
ESR1 mutation (ligand-binding domain, usually in ctDNA) ESR1 ESR1 mutations arise in the oestrogen receptor's ligand-binding domain after aromatase inhibitor treatment, letting the receptor work without oestrogen. They are usually found in a blood test and select the oral SERDs elacestrant and imlunestrant. | HR-positive / HER2-negative breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors | none | biomarker, hormone-receptor | ||
HER3 ERBB3 HER3 is a cousin of HER2 that cancers use as an escape route when HER2 or EGFR are blocked. | Triple-negative breast cancer, Non-small-cell lung cancer, HR-positive / HER2-negative breast cancer | none | adc-target |
